Kidney Function Tests Market Outlook 2031:
The kidney function tests market size was valued at USD 876.40 Million in 2022 and is projected to reach USD 1.50 Billion by 2031, expanding at a CAGR of 6.2% during the forecast period 2023 - 2031. The growth of the market is attributed to the factors such as the rising number of market player acquisitions, increase in R&D programs, high incidence of kidney disease, and growing number of government initiatives.
Kidney function tests are basic laboratory tests that are used to investigate and evaluate kidney functions. Kidneys remove waste, extra fluid, & toxins from the blood as well as remove acid that is produced by the cells of the body. Kidneys maintain a healthy balance of water, minerals, and salts including sodium, phosphorus, potassium, & calcium from the body. However, in some cases, calcium combines with oxalate and forms a calcium oxalate stone in the urine and causes kidney stones.
Further, it prevents the body from absorbing beneficial nutrients. Therefore, a kidney function test is recommended to check how well the kidneys are working. According to various reports, an increased intake of fluids reduces the risk of stone formation.
Thus, recent guidelines recommend drinking enough fluids to increase urine output. In addition to kidney stones, diabetes insipidus, ectopia kidney, glomerular diseases, and kidney failure all come under kidney diseases.
The market report finds that the COVID-19 pandemic has further catapulted the demand for kidney function tests. According to the research conducted by National Kidney Foundation, people hospitalized due to COVID-19 are at a high risk of developing AKI. Moreover, as per healthcare officials, COVID-19 patients with an AKI need to be screened regularly, as their risk of developing CKD is greater than that of other patients.
In January 2020, SphingoTec GmbH, a Germany-based company, launched IB10 sphingotestpenKid, a point-of-care (PoC) test for Proenkephalin (penKid). With this biomarker, a standard blood test can be used to assess kidney function in real-time. Elypta AB, a Sweden-based healthcare service provider, raised USD 7.0 million in a seed round in January 2020, to create the first urine test for kidney cancer.
CKD has evolved into a major public health problem with a high financial cost. According to the National Institutes of Health (NIH), the global prevalence of CKD is about 14%. Furthermore, the prevalence of CKD-related risk factors such as diabetes, hypertension, and obesity is increasing, due to lifestyle changes.
As a result, the demand for mandatory CKD screening tests among patients with hypertension and diabetes is rising. According to the International Diabetes Federation, in 2020, 463.0 million adults worldwide were suffering from diabetes. This number is expected to rise to 700 million during the forecast period.
Kidney Function Tests Market Trends, Drivers, Restraints, and Opportunities:
- Rising R&D initiatives for the production of novel products is expected to the boost market.
- Increasing number of COVID-19 patients is likely to propel the demand for kidney function tests in the coming years.
- Growing investments in the field of kidney function testing are expected to propel the market.
- Rising investments in the kidney function testing sector is expected to drive the market.
- Requirement for routine tests for diabetic patients to keep a tab on kidney disease is projected to the boost market.
Scope of Kidney Function Tests Market Report
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Kidney Function Tests Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Product (Clearance Tests and Urine Tests) and End-user (Hospitals, Diagnostic Laboratories, and Institutes)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Abbott.; Danaher.; F. Hoffmann-La Roche Ltd; Sysmex Corporation; Siemens Healthcare GmbH; Randox Laboratories Ltd.; Quest Diagnostics Incorporated; ACON Laboratories, Inc.; Nova Biomedical; and Laboratory Corporation of America Holdings |
Kidney Function Tests Market Segment Insights:
Based on product, the global market is bifurcated into clearance tests and urine tests. The clearance test segment accounts for a key share of the market; however, this segment is anticipated to expand at a rapid pace during the forecast period. The clearance tests segment held a market share of 29% in 2020 and its share is projected to rise in the coming years.
Glomerular filtration rate (GFR) is a clearance test used to diagnose kidney diseases. Furthermore, these tests ensure that output varies minimally due to their high sensitivity and accuracy. These products are becoming extensively used due to their low cost and widespread availability.
The urine tests segment is projected to grow at a fast pace during the forecast period, as they are extensively used for diagnosing a wide range of ailments, including UTIs, diabetes, kidney stones, high blood pressure, and pregnancy.
Increasing usage of Percutaneous Nephrostomy Catheters for urine tests and for the diagnosis of kidney stones as the nephrostomy tube provides an entrance into the kidney to take out the stones. Increasing preference for POC diagnostics with the identification of prescription drug abuse which can be achieved with urine tests is expected to drive the segment.
On the basis of end-user, the kidney function tests market is divided into hospitals, diagnostic laboratories, and institutes. In 2020, the hospitals segment accounted for a dominant share of the market, and this is expected to continue during the forecast period. The large share of the market is attributed to the increase in hospital visits, due to rising awareness regarding CKD and its management.
Furthermore, the segment share is likely to increase boosted due to the development and launch of sophisticated infrastructures across various regions that aid in the performance of efficient diagnostic procedures. The segment is expected to be driven by favorable reimbursement scenarios, and steps taken by healthcare organizations around the world to encourage the use of advanced diagnostic tests.
The diagnostic laboratories segment is expected to take a substantial share of the market by 2028, as they are cost-effective, can perform many tests at a time, and provide reliable results. The diagnostic laboratories and institutes segments in North America and Europe are expected to grow at a fast pace during the forecast period due to increasing in R&D activities in these regions.
In terms of region, the global kidney function tests market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a key share of the market in 2020, due to the presence of a well-established healthcare system, high knowledge levels about CKD, favorable reimbursement policies, and government initiatives.
The region is estimated to retain its dominance during the study period. The US held a major share of the market in North America, due to the presence of major players and the availability of advanced technology.
The market in Asia Pacific is anticipated to expand at a fast pace during the forecast period, due to rapidly expanding healthcare facilities and increasing investments by leading market players in the region. Furthermore, the emergence of a large target population in emerging countries such as China and India is expected to propel the market in the region during the forecast period.
Segments
The global kidney function tests market has been segmented on the basis of
Product
- Clearance Test
- Urine Test
End user
- Hospitals
- Diagnostic Laboratories
- Institutes
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Abbott.
- Danaher.
- F. Hoffmann-La Roche Ltd
- Sysmex Corporation
- Siemens Healthcare GmbH
- Randox Laboratories Ltd.
- Quest Diagnostics Incorporated
- ACON Laboratories, Inc.
- Nova Biomedical
- Laboratory Corporation of America Holdings
Competitive Landscape
Major players operating in the market include Abbott.; Danaher.; F. Hoffmann-La Roche Ltd; Sysmex Corporation; Siemens Healthcare GmbH; Randox Laboratories Ltd.; Quest Diagnostics Incorporated; ACON Laboratories, Inc.; Nova Biomedical; and Laboratory Corporation of America Holdings.
These players are pursuing growth strategies such as alliances and partnerships to broaden their geographical scope.
Request For Customization
Enquiry Before Buying
Speak With Analyst
